Navigation Links
First come, first served?
Date:12/30/2010

Emergency department overcrowding can result in long waiting times for seriously ill patients. They then compete with patients with less severe illnesses for the next available treatment. In this edition of Deutsches rzteblatt International (Dtsch Arztebl Int 2010; 107[50]: 892𔃆), Michael Christ and his coauthors provide an overview of current practice for initial assessment of emergency patients.

Triage provides reliable methods that can be used to assess the severity of an illness and the urgency of treatment in emergency departments.

In English-speaking countries, five-level triage systems are already being successfully applied. For example, trained nursing staff uses them to ascertain whether basic life support is needed, whether patients are in severe pain, or whether further diagnostic procedures are needed. Triage can significantly improve the mostly subjective assessment methods used in Germany. In Australia it is already improving patient safety, reducing their waiting times, and increasing the professional satisfaction of emergency department staff.

The authors' own experience shows that trained, specialized staff can use a German translation of the Emergency Severity Index to assess emergency patients in Germany reliably, too.


'/>"/>

Contact: Dr. Michael Christ
michael.christ@klinikum-nuernberg.de
Deutsches Aerzteblatt International
Source:Eurekalert

Page: 1

Related biology news :

1. Longevinex exhibits L-shaped safety curve for first time in resveratrol biology
2. Experts converge at Arizona State University for first preventive cancer vaccine conference
3. Hoyos Corporation Rolls Out First Iris-Biometrics System Priced to Compete with Generic Card Readers
4. Metabolism models may explain why Alzheimers disease kills some neuron types first
5. Scientists announce discovery of first horned dinosaur from South Korea
6. Researchers describe first functioning lipidome of mouse macrophage
7. Genome 10K Project announces first 101 species for genome sequencing
8. First-ever covalent irreversible inhibition of a protease central to hepatitis C infection
9. New guidance issued for first responders collecting suspected biothreat agents
10. First volume of new laboratory manual series on imaging is released
11. LSUHSC reports first successful salivary stone removal with robotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/1/2017)... 2017 IDTechEx Research, a leading provider of ... the availability of a new report, Sensors for Robotics: Technologies, ... Reading ... ... Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/24/2017)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing ... Leader event to highlight new clinical data that will ... the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the Company,s ... in-person and via live webcast on Tuesday, February 28 ... the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) ... pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has ... Johnson Innovation – JJDC, Inc. (JJDC) as the lead ... Biotechnology Partners, and Genesys Capital, as well as founding ... ...
Breaking Biology Technology: